Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization
The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective.
The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective.